Please login to the form below

Not currently logged in
Email:
Password:

Prexton

This page shows the latest Prexton news and features for those working in and with pharma, biotech and healthcare.

Lundbeck bolts on migraine drug via $1.95bn deal to buy Alder

Lundbeck bolts on migraine drug via $1.95bn deal to buy Alder

$1b purchase of  Prexton Therapeutics and phase 2 Parkinson’s disease therapy foliglurax.

Latest news

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics